序号 |
标题 |
次数 |
作者 |
发布时间 |
62506 |
CAS: 2285373-84-2 Ethyl (S)-1-((1-((4-((((4-nitrophenoxy)carbonyl) oxy)methyl)phenyl)amino)-1-oxo-5-ureidopenta n-2-yl)carbamoyl)cyclobutane-1-carboxylate |
129 |
WYQ |
2024-12-19 |
62507 |
Azido-Phenyl-Amido-SS-Sulfo-NHS Ester, ADC试剂 |
82 |
kx |
2024-12-19 |
62508 |
DOTA-βala-K-NOTA-BBN(7-14)NH2 |
93 |
h |
2024-12-19 |
62509 |
DBCO-PEG3-acetic-Val-Cit-PAB,主要用于合成抗体偶联药物(ADC) |
79 |
WYQ |
2024-12-19 |
62510 |
Mal-PEG4-Val-Ala-PAB-PNP,ADC定制 |
62 |
wyh |
2024-12-19 |
62511 |
cas:330970-70-2 Alloc-Val-Ala-OH |
77 |
zyl |
2024-12-19 |
62512 |
DOTA-somatostatin receptor analogs DOTA生长抑素受体类似物 |
62 |
h |
2024-12-19 |
62513 |
CAS: 2754384-60-4,DBCO-(PEG)3-VC-PAB-MMAE |
62 |
WYQ |
2024-12-19 |
62514 |
Fmoc-Gln(Trt)-PAB-OH, ADC试剂 |
97 |
kx |
2024-12-19 |
62515 |
CAS: 2994332-18-0 ,DBCO-C4-Val-Cit-PABC-PNP,二苯并环辛炔-C4-缬氨酸-瓜氨酸-PABC-对硝基苯基磷酸酯 |
74 |
WYQ |
2024-12-19 |
62516 |
cas:159857-60-0,Fmoc-Lys(MMt)-OH,N-[(9H-芴-9-基甲氧基)羰基]-N'-[(4-甲氧基苯基)二苯基甲基]-L-赖氨酸 |
153 |
kx |
2024-12-19 |
62517 |
DBCO-PEG3-Val-Cit-PAB-PNP,二苯并环辛炔-三聚乙二醇-缬氨酸-瓜氨酸-PAB-PNP |
105 |
WYQ |
2024-12-19 |
62518 |
NOTA-anti-HER2 NOTA标记抗人表皮生长因子受体2型(HER2)纳米体 |
102 |
h |
2024-12-19 |
62519 |
cas:186023-44-9 Fmoc-Ala-Pro-OH |
93 |
zyl |
2024-12-19 |
62520 |
TCO-PEG4-Val-Cit-PAB-PNP,反式环辛烯-四聚乙二醇-缬氨酸-瓜氨酸-PAB-PNP |
71 |
WYQ |
2024-12-19 |
62521 |
Boc-Val-Cit CAS:870487-08-4 |
89 |
zyl |
2024-12-19 |
62522 |
DOTA-Bn-FGK-Fab DOTA标记抗体片段 |
99 |
h |
2024-12-19 |
62523 |
cas:252554-78-2,Fmoc-Ala-Ser (Psi(Me,Me)pro)-OH,(4S)-3-[(2S)-2-[[(9H-芴-9-甲氧基)羰基]氨基]-1-氧代丙基]-2,2-二甲基-4-恶唑烷羧酸 |
56 |
kx |
2024-12-19 |
62524 |
DOTA-Nal3-Octreotide DOTANOC DOTA-Nal3-奥曲肽 |
91 |
h |
2024-12-19 |
62525 |
cas:2413428-36-9,MC-Gly-Gly-Phe-Gly,(S)-5-苄基-18-(2,5-二氧代-2,5-二氢-1H-吡咯-1-基)-4,7,10,13-四氧代-3,6,9,12-四氮杂十八烷-1-酸 |
73 |
kx |
2024-12-19 |
62526 |
MC-Val-Cit-PAB-PNP CAS:159857-81-5 |
109 |
zyl |
2024-12-19 |
62527 |
cas:2353409-52-4,Mal-amido-PEG8-Val-Gly-PAB-OH,马来酰亚胺-酰胺-八聚乙二醇-VAL-GLY-PAB-羟基 |
65 |
kx |
2024-12-19 |
62528 |
Fmoc-PEG3-Ala-Ala-Asn(Trt)-PAB CAS:2055042-69-6 |
65 |
zyl |
2024-12-19 |
62529 |
cas:1895916-22-9,MC-Val-Ala-OH, ADC试剂 |
66 |
kx |
2024-12-19 |
62530 |
cas:159857-70-2,MC-Val-Cit-Doxorubicin,MC-VAL-CIT-阿霉素 |
58 |
kx |
2024-12-19 |
62531 |
DOTA−Gal-NAPamide DOTA−Gal-纳帕胺 |
64 |
h |
2024-12-19 |
62532 |
DOTA-peptide-Lym-1 radioimmunotherapy DOTA-肽-Lym-1 |
76 |
h |
2024-12-19 |
62533 |
N-DBCO-N-bis(PEG2-amide-PEG4-Val-cit-PAB-MMAE), N-二苯并环辛炔-N-双(二聚乙二醇-酰胺-四聚乙二醇-VAL-CIT-PAB-MMAE) |
84 |
kx |
2024-12-19 |
62534 |
DOTA-dGlu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2 |
85 |
h |
2024-12-19 |
62535 |
DOTA-MGO DOTA-DGlu-(Glu)s-minigastrin |
69 |
h |
2024-12-19 |
62536 |
cas:2762518-86-3,NHS Ester-PEG4-Val-Cit-PAB-MMAE, ADC试剂 |
119 |
kx |
2024-12-19 |
62537 |
DOTA-scFv-anti-PSMA DOTA-scFv-抗PSMA脂质纳米粒(LNPs) |
69 |
h |
2024-12-19 |
62538 |
cas:2353409-45-5,BCN-PEG3-Val-Cit-PFP Ester, ADC试剂 |
64 |
kx |
2024-12-19 |
62539 |
cas:2112738-13-1,Mal-amido-PEG2-Val-Cit-PAB-PNP, ADC试剂 |
69 |
kx |
2024-12-19 |
62540 |
cas:2055041-39-7,Mal-PEG4-Val-Cit-PAB-OH, ADC试剂 |
66 |
kx |
2024-12-19 |
62541 |
cas:2055024-62-7,NH2-PEG3-Val-Cit-PAB-OH, ADC试剂 |
117 |
kx |
2024-12-19 |
62542 |
Fmoc-PEG3-Val-Cit,N-芴甲氧羰基-三聚乙二醇-VAL-CIT |
84 |
kx |
2024-12-19 |
62543 |
DOTA-anti-VLA-4 |
70 |
h |
2024-12-19 |
62544 |
DOTA-glycylglycylglycyl-l-p-isothiocyanatophenylalanine amide |
73 |
h |
2024-12-19 |
62545 |
CAS: 2748039-76-9, Alkyne-Val-Cit-PAB-FAM,炔-Val-Cit-PAB-FAM |
65 |
WYQ |
2024-12-19 |
62546 |
CAS:646502-53-6 MC-Val-Cit-PAB-MMAE的结构式 |
93 |
zyl |
2024-12-19 |
62547 |
Amino-PEG2-VG-N-Bis(PEG1-azide),氨基-二聚乙二醇-VG-N-双(一聚乙二醇-叠氮) |
81 |
WYQ |
2024-12-19 |
62548 |
Azido-PEG8-Val-Cit-PAB-PNP,C34H47N9O12 |
81 |
WYQ |
2024-12-19 |
62549 |
化合物:TCO-MMAE,反式环辛烯-MMAE(其中MMAE为单甲基澳瑞他汀E的缩写) |
110 |
WYQ |
2024-12-19 |
62550 |
cas:2748039-77-0,Alkyne-Val-Cit-PAB-PNP,炔-VAL-CIT-PAB-PNP 酯 |
78 |
kx |
2024-12-19 |